02/12/2022 - Press release
The Hospital del Mar Medical Research Institute is leading the study that will evaluate whether a new molecule can be used to improve the cognitive performance of people with Down syndrome. The study is part of the ICOD project for the improvement of cognition in Down syndrome, promoted by the European Union, which is funding a project of this type for the first time. The treatment has already passed the trial phase with volunteers without Down syndrome, which sought to certify the safety and tolerability of the medicine. In this new phase, the safety of the treatment in people with Down syndrome will be validated and the first indications of effectiveness will be obtained. It is estimated that results may be available by mid-2023.
16/11/2022 - Press release
A study led by the Hospital del Mar Medical Research Institute, the Barcelonaβeta Brain Research Centre (BBRC), a research unit from the Pasqual Maragall Foundation, and the University of Gothenburg, has compared the validity of nine biomarkers for the day-to-day diagnosis of Alzheimer's disease in hospital centres. The work involved a cohort of patients from Hospital del Mar with various neurological pathologies. The researchers analysed the presence of nine variants of the Tau protein in blood samples from these people. Some of these blood markers are just as useful for detecting Alzheimer's as those measured in the reference test used, namely the analysis of cerebrospinal fluid obtained by lumbar puncture. Less invasive plasma biomarker determinations than those performed after a lumbar puncture may provide a tool for improving the diagnosis of Alzheimer's disease and determining which individuals should undergo further testing to confirm the diagnosis. The work has been published in the leading journal in this field, Alzheimer's & Dementia.
03/11/2022 - Press release
A study led by researchers at the Hospital del Mar Medical Research Institute links psychological trauma in childhood with an increased risk of developing some kind of mental disorder years later. This is the first study to analyse the relationship between psychological trauma and various mental pathologies at a transdiagnostic level. It examines fourteen already published reviews or meta-analyses, involving more than 90,000 participants. The study is published in the European Archives of Psychiatry and Clinical Neuroscience and demonstrates the need to study the history of patients suffering from a mental disorder.
26/10/2022 - Press release
People with low levels of this compound who suffer this pathology have almost a 40% greater risk of dying or being admitted to hospital than those with higher levels. This is according to a study carried out jointly by Hospital Germans Trias i Pujol and the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar). The research team analysed blood samples from 905 patients with heart failure, who were monitored for three years. The results of the study have been published in the Journal of the American College of Cardiology.
19/10/2022 - Press release
A multicentre study involving hospitals in Spain and Portugal, led by Hospital del Mar, shows that these patients already receive enough radiation to treat the disease when the breast affected by the tumour is irradiated directly. The study monitored more than 400 women. The results indicate that the five-year survival rate and relapses are practically identical between those who underwent specific treatment targeting the nodes located in the armpits and those who only received breast radiation. The findings of the OPTIMAL study have been published in the journal Radiation Oncology and can now be applied to clinical practice. Thanks to this fact, patients will need less radiotherapy and will suffer fewer treatment-related side effects.
05/10/2022 - Press release
A study led by researchers at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) has determined the role that fibroblasts, the cells that contribute to tissue formation, play in a tumour's ability to generate resistance to the most common biological treatment for HER2. The paper, published in the journal Nature Communications, demonstrates the ability of a new therapy, currently undergoing clinical trials, to promote a potent immune response by binding to the fibroblasts, enabling it to overcome resistance to anti-HER2 therapy in tumours with this cancer cell protection mechanism. To demonstrate this, the researchers created a 3D tumour model in which they were able to check the relationships between all the factors involved.
12/09/2022 - Press release
Patients admitted due to SARS-CoV-2 infection with imbalanced levels of two immune system cells, CD4 and CD8 T lymphocytes, have a worse prognosis and a higher risk of death. Having more than twice the number of CD4 lymphocytes than CD8 lymphocytes increases the probability of dying from the infection by 4.6 times and the chances of experiencing respiratory distress by two times, according to a study by physicians and researchers from Hospital del Mar, the Hospital del Mar Medical Research Institute, Universitat Pompeu Fabra, and CIBERINFEC, published in the journal Frontiers in Medicine. This finding leads the study's authors to recommend a more aggressive therapeutic approach for these patients from the moment of admission. Additionally, they believe that this situation may be repeated in other viral infections.
11/08/2022 - Press release
The research, led by the Barcelonaβeta Brain Research Center (BBRC), research center of the Pasqual Maragall Foundation, the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and the University of Gothenburg, has been published in the prestigious journal Nature Medicine. The study, which used data from almost 400 participants of the ALFA+ Study, which has the impetus of the "la Caixa" Foundation, determines that the biomarkers p-tau231 and p-tau217 measured in the blood are suitable for indicating brain changes related to the amyloid protein in people without cognitive symptoms. The results of this research make p-tau231 a very promising blood biomarker to detect early those middle-aged people who show the first brain changes associated with Alzheimer's and to conduct clinical trials aimed at this early stage of Alzheimer's.
28/07/2023 - Press release
A study by cardiologists at Hospital del Mar and researchers at the Hospital del Mar Medical Research Institute reveals that more than half of the people treated for the arrhythmia known as atrial flutter will suffer an episode of atrial fibrillation in less than a year. The risk of atrial fibrillation reaches 86% in those patients who score higher on a risk scale designed by the team, prompting the need for more accurate monitoring of these patients because of the likelihood that they could suffer other cardiovascular problems, such as a stroke. The study, published in the Journal of Cardiology, was funded by the 2014 La Marató de TV3, dedicated to heart disease.
Més informació "Patients with arrhythmia are at greater risk of suffering atrial fibrillation"
30/05/2022 - Press release
A group of genes has been identified in cancerous cells that survive chemotherapy treatment. The activity of these genes leads to treatment resistance and increased capacity for metastasis. This breakthrough opens the door to studying targeted treatments using drug inhibitors of these genes combined with chemotherapy, potentially providing alternatives for patients with a worse prognosis in this type of tumor, accounting for 30% of cases. The research, led by scientists from the Hospital del Mar Medical Research Institute, highlights that this type of tumor cell reverts to an embryonic state. Identifying the factor that triggers this change could aid in designing new treatments for high-risk patients.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
